Nestle SA (NSRGY.PK,NSTR.L) said, in an update on results of tender offer for Aimmune Therapeutics (AIMT), that about 43.44 million Aimmune shares were validly tendered. It represented about 84% of the outstanding shares of Aimmune.
The minimum tender condition to the consummation of the offer has been satisfied, Nestle
said.
In late-August, Nestlé offered to buy Aimmune Therapeutics for $34.50 per share. The offer expired on October 9, 2020.
For comments and feedback contact: editorial@rttnews.com
Business News